Senstend

RSS

Withdrawn

This medicine's authorisation has been withdrawn

lidocaine / prilocaine
MedicineHumanWithdrawn

Irish is available via eTranslation, the European Commission's machine translation service.

Translate to Irish | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 24 June, the European Commission withdrew the marketing authorisation for Senstend (lidocaine / prilocaine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Plethora Pharma Solutions Limited, which notified the European Commission of its decision not to market the product in the EU for commercial reasons. 

Senstend was granted marketing authorisation in the EU on 14 November 2019 for the treatment of primary premature ejaculation. The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU since its approval in 2019. Senstend was a duplicate application to Fortacin, which is marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for Fortacin. 

The European Public Assessment Report (EPAR) for Senstend is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (1.29 MB - PDF)

Amharc

español (ES) (1.22 MB - PDF)

Amharc

čeština (CS) (1.27 MB - PDF)

Amharc

dansk (DA) (1.22 MB - PDF)

Amharc

Deutsch (DE) (1.22 MB - PDF)

Amharc

eesti (ET) (1.21 MB - PDF)

Amharc

ελληνικά (EL) (1.28 MB - PDF)

Amharc

français (FR) (1.22 MB - PDF)

Amharc

hrvatski (HR) (1.24 MB - PDF)

Amharc

italiano (IT) (686.49 KB - PDF)

Amharc

latviešu (LV) (752.95 KB - PDF)

Amharc

lietuvių (LT) (711.1 KB - PDF)

Amharc

magyar (HU) (1.27 MB - PDF)

Amharc

Malti (MT) (747.25 KB - PDF)

Amharc

Nederlands (NL) (687.46 KB - PDF)

Amharc

polski (PL) (744.53 KB - PDF)

Amharc

português (PT) (688.19 KB - PDF)

Amharc

română (RO) (708.86 KB - PDF)

Amharc

slovenčina (SK) (743.36 KB - PDF)

Amharc

slovenščina (SL) (701.62 KB - PDF)

Amharc

suomi (FI) (1.21 MB - PDF)

Amharc

svenska (SV) (666.47 KB - PDF)

Amharc

Product information

български (BG) (1.64 MB - PDF)

Amharc

español (ES) (1.66 MB - PDF)

Amharc

čeština (CS) (1.37 MB - PDF)

Amharc

dansk (DA) (914.89 KB - PDF)

Amharc

Deutsch (DE) (1.01 MB - PDF)

Amharc

eesti (ET) (985.34 KB - PDF)

Amharc

ελληνικά (EL) (1.71 MB - PDF)

Amharc

français (FR) (926.09 KB - PDF)

Amharc

hrvatski (HR) (831.74 KB - PDF)

Amharc

italiano (IT) (917.55 KB - PDF)

Amharc

latviešu (LV) (1.46 MB - PDF)

Amharc

lietuvių (LT) (1.01 MB - PDF)

Amharc

magyar (HU) (882.02 KB - PDF)

Amharc

Malti (MT) (1.42 MB - PDF)

Amharc

Nederlands (NL) (917.64 KB - PDF)

Amharc

polski (PL) (1.45 MB - PDF)

Amharc

português (PT) (993.24 KB - PDF)

Amharc

română (RO) (1.02 MB - PDF)

Amharc

slovenčina (SK) (1.43 MB - PDF)

Amharc

slovenščina (SL) (1.46 MB - PDF)

Amharc

suomi (FI) (993.89 KB - PDF)

Amharc

svenska (SV) (919.07 KB - PDF)

Amharc

Íslenska (IS) (806.43 KB - PDF)

Amharc

norsk (NO) (989.64 KB - PDF)

Amharc
14/11/2019
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (690.65 KB - PDF)

Amharc

español (ES) (619.32 KB - PDF)

Amharc

čeština (CS) (680 KB - PDF)

Amharc

dansk (DA) (619.86 KB - PDF)

Amharc

Deutsch (DE) (620.79 KB - PDF)

Amharc

eesti (ET) (618 KB - PDF)

Amharc

ελληνικά (EL) (687.72 KB - PDF)

Amharc

français (FR) (620.68 KB - PDF)

Amharc

hrvatski (HR) (662.45 KB - PDF)

Amharc

italiano (IT) (619.23 KB - PDF)

Amharc

latviešu (LV) (681.09 KB - PDF)

Amharc

lietuvių (LT) (663.74 KB - PDF)

Amharc

magyar (HU) (678.77 KB - PDF)

Amharc

Malti (MT) (681.6 KB - PDF)

Amharc

Nederlands (NL) (617.33 KB - PDF)

Amharc

polski (PL) (680.16 KB - PDF)

Amharc

português (PT) (619.33 KB - PDF)

Amharc

română (RO) (663.19 KB - PDF)

Amharc

slovenčina (SK) (679.4 KB - PDF)

Amharc

slovenščina (SL) (676.69 KB - PDF)

Amharc

suomi (FI) (617.2 KB - PDF)

Amharc

svenska (SV) (619.13 KB - PDF)

Amharc

Íslenska (IS) (826.65 KB - PDF)

Amharc

norsk (NO) (619.89 KB - PDF)

Amharc

Product details

Name of medicine
Senstend
Active substance
  • lidocaine
  • prilocaine
International non-proprietary name (INN) or common name
  • lidocaine
  • prilocaine
Therapeutic area (MeSH)
Premature Ejaculation
Anatomical therapeutic chemical (ATC) code
N01BB20

Pharmacotherapeutic group

Anesthetics

Therapeutic indication

Senstend is indicated for the treatment of primary premature ejaculation in adult men.

Authorisation details

EMA product number
EMEA/H/C/005298
Marketing authorisation holder
Plethora Pharma Solutions Limited

32 Merrion Street
Upper Dublin 2
Ireland

Opinion adopted
19/09/2019
Marketing authorisation issued
14/11/2019

Assessment history

This page was last updated on

Share this page